In the second half of the 1980s, ciprofloxacin became the first widely available fluoroquinolone. Moreover, It is a potent bactericidal agent against gram-positive and negative together with a variety of bacterial infections. Despite the resistance of uropathogens to ampicillin and TMP/SMX, It is susceptible to the ciprofloxacin.[88] Ciprofloxacin XR 500 was approved in December 2002 for the treatment of uncomplicated urinary tract infections. Additionally, The Cipro XR 100 is submitted to treat the patients with complicated urinary tract infection including acute uncomplicated pyelonephritis, which the agency approved it in 2003 under NDA 021554. Earlier, Ciprofloxacin was marketed under the trade name Cipro (oral suspension) and Cipro
